Globus Medical Inc. Class A Common Stock vs PBF Energy Inc. Class A Common Stock — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while PBF Energy Inc. Class A Common Stock trades at $89.57 (market cap $10.61B). The key difference: Globus Medical Inc. Class A Common Stock and PBF Energy Inc. Class A Common Stock are close in size by market cap, and PBF Energy Inc. Class A Common Stock pays a 1.23% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and PBF Energy Inc. Class A Common Stock for 1 Days on average.
| GMED | PBF | |
|---|---|---|
Market Cap | $10.25B | $10.61B |
Volume | 1,059,528 | 2,976,892 |
Sector | Health | Energy |
52-Week High | $96.82 | $91.17 |
52-Week Low | $58.33 | $26.02 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $9.76B | $12.23B |
Dividend Yield | — | 1.23% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
PBF Energy trades at $91.17, up 7.23% in the last 24 hours and near its 52-week high, reflecting strong bullish momentum. The stock shows robust technical strength with a bullish moving average signal and trades above key support levels. Fundamentally, the company is transitioning from a net loss of $158.5 million in 2025 to a projected net profit of $1.4 billion in 2026, driven by restored refinery operations and significant debt reduction. Recent earnings beats, including a Q2 2026 EPS of $6.22 versus $4.15 expected, highlight operational improvements.
The outlook for PBF is positive with strong earnings growth and discounted valuation metrics, but risks include volatile refining margins and geopolitical influences on oil prices. Analyst sentiment is mixed with a consensus price target of $88.75, below the current price, suggesting caution despite the bullish technical setup. Investors should weigh the strong profitability rebound against potential headwinds from energy market fluctuations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →PBF Energy refines and markets petroleum products, including gasoline, diesel, and jet fuel. It also operates logistics assets supporting its refining business.
Read more on PBF →